Nanobiotix (NBTX) Non-Current Assets (2018 - 2025)
Nanobiotix (NBTX) posted Non-Current Assets of $5.8 million for Q4 2025, down 8.29% on a QoQ basis from $6.4 million in Q4 2024, and down 8.29% year-over-year from $6.4 million in Q4 2024.
Nanobiotix (NBTX) has 8 years of Non-Current Assets data on file, last reported at $5.8 million in Q4 2025.
- In Q4 2025, Non-Current Assets fell 8.29% year-over-year to $5.8 million; the TTM figure through Dec 2025 stood at $5.8 million (down 8.29% YoY), while the FY2025 annual figure was $5.7 million, down 12.12% from the prior year.
- Non-Current Assets retreated to $5.8 million in Q4 2025, from $6.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.0 million in Q4 2021 and bottomed at $5.8 million in Q4 2025.
- A 5-year average of $7.4 million and a median of $7.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets decreased 4.85% — and 2022, when it slipped 24.1%.
- Year by year, Non-Current Assets stood at $10.0 million in 2021, then slipped by 24.1% to $7.6 million in 2022, then decreased by 6.69% to $7.1 million in 2023, then fell by 9.88% to $6.4 million in 2024, then decreased by 8.29% to $5.8 million in 2025.
- The last three Non-Current Assets figures came in at $5.8 million (Q4 2025), $6.4 million (Q4 2024), and $7.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 285.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.83 Mn |
| Jun 30, 2025 | 5.98 Mn |
| Dec 31, 2024 | 6.36 Mn |
| Jun 30, 2024 | 6.70 Mn |
| Dec 31, 2023 | 7.06 Mn |
| Jun 30, 2023 | 7.38 Mn |
| Dec 31, 2022 | 7.56 Mn |
| Jun 30, 2022 | 8.29 Mn |
| Dec 31, 2021 | 9.96 Mn |
| Jun 30, 2021 | 9.69 Mn |
| Dec 31, 2020 | 10.47 Mn |
| Dec 31, 2019 | 11.16 Mn |
| Dec 31, 2018 | 4.05 Mn |